dc.contributor.author
Risson, Valérie
dc.contributor.author
Mazelin, Laetitia
dc.contributor.author
Roceri, Mila
dc.contributor.author
Sanchez, Hervé
dc.contributor.author
Moncollin, Vincent
dc.contributor.author
Corneloup, Claudine
dc.contributor.author
Richard-Bulteau, Hélène
dc.contributor.author
Vignaud, Alban
dc.contributor.author
Baas, Dominique
dc.contributor.author
Defour, Aurélia
dc.contributor.author
Freyssenet, Damien
dc.contributor.author
Tanti, Jean-François
dc.contributor.author
Le-Marchand-Brustel, Yannick
dc.contributor.author
Ferrier. Bernard
dc.contributor.author
Conjard-Duplany, Agnès
dc.contributor.author
Romanino, Klaas
dc.contributor.author
Bauché, Stéphanie
dc.contributor.author
Hantaï, Daniel
dc.contributor.author
Mueller, Matthias
dc.contributor.author
Kozma, Sara C
dc.contributor.author
Thomas, George
dc.contributor.author
Rüegg, Markus A.
dc.contributor.author
Ferry, Arnaud
dc.contributor.author
Pende, Mario
dc.contributor.author
Bigard, Xavier
dc.contributor.author
Koulmann, Nathalie
dc.contributor.author
Schaeffer, Laurent
dc.contributor.author
Gangloff, Yann-Gael
dc.date.issued
2022-11-03T19:12:23Z
dc.date.issued
2022-11-03T19:12:23Z
dc.date.issued
2022-11-03T19:12:23Z
dc.identifier
https://hdl.handle.net/2445/190447
dc.description.abstract
Mammalian target of rapamycin (mTOR) is a key regulator of cell growth that associates with raptor and rictor to form the mTOR complex 1 (mTORC1) and mTORC2, respectively. Raptor is required for oxidative muscle integrity, whereas rictor is dispensable. In this study, we show that muscle-specific inactivation of mTOR leads to severe myopathy, resulting in premature death. mTOR-deficient muscles display metabolic changes similar to those observed in muscles lacking raptor, including impaired oxidative metabolism, altered mitochondrial regulation, and glycogen accumulation associated with protein kinase B/Akt hyperactivation. In addition, mTOR-deficient muscles exhibit increased basal glucose uptake, whereas whole body glucose homeostasis is essentially maintained. Importantly, loss of mTOR exacerbates the myopathic features in both slow oxidative and fast glycolytic muscles. Moreover, mTOR but not raptor and rictor deficiency leads to reduced muscle dystrophin content. We provide evidence that mTOR controls dystrophin transcription in a cell-autonomous, rapamycin-resistant, and kinase-independent manner. Collectively, our results demonstrate that mTOR acts mainly via mTORC1, whereas regulation of dystrophin is raptor and rictor independent.
dc.format
application/pdf
dc.publisher
Rockefeller University Press
dc.relation
Reproducció del document publicat a: https://doi.org/10.1083/jcb.200903131
dc.relation
Journal of Cell Biology, 2009, vol. 187, num. 6, p. 859-874
dc.relation
https://doi.org/10.1083/jcb.200903131
dc.rights
cc-by (c) Risson, Valérie et al., 2009
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Ciències Fisiològiques)
dc.subject
Proteïnes portadores
dc.subject
Malalties musculars
dc.subject
Carrier proteins
dc.subject
Muscular Diseases
dc.title
Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion